-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Abbott Laboratories Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$34.61 B | $43.08 B | $43.65 B | $40.11 B | $41.95 B |
| Cost of Revenue |
|
$15.00 B | $18.54 B | $19.14 B | $17.98 B | $18.71 B |
| Gross Profit |
|
$19.61 B | $24.54 B | $24.51 B | $22.13 B | $23.24 B |
| Research & Development |
|
$2.42 B | $2.74 B | $2.89 B | $2.74 B | $2.84 B |
| Selling,General & Administrative |
|
$9.70 B | $11.32 B | $11.25 B | $10.95 B | $11.70 B |
| Operating Expense |
|
$14.25 B | $16.11 B | $16.15 B | $15.66 B | $16.42 B |
| Operating Income |
|
$5.36 B | $8.43 B | $8.36 B | $6.48 B | $6.83 B |
| Net Income |
|
$4.50 B | $7.07 B | $6.93 B | $5.72 B | $13.40 B |
Abbott Laboratories Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$7.15 B | $10.25 B | $10.17 B | $7.28 B | $7.97 B |
| Inventories |
|
$5.01 B | $5.16 B | $6.17 B | $6.57 B | $6.19 B |
| Total Current Assets |
|
$20.44 B | $24.24 B | $25.22 B | $22.67 B | $23.66 B |
| Property,Plant and Equipment |
|
$9.03 B | $8.96 B | $9.16 B | $11.28 B | $10.66 B |
| Goodwill |
|
$23.74 B | $23.23 B | $22.80 B | $23.68 B | $23.11 B |
| Total Assets |
|
$72.55 B | $75.20 B | $74.44 B | $73.21 B | $81.41 B |
| Total Liabilities |
|
$39.55 B | $39.17 B | $37.53 B | $34.39 B | $33.51 B |
| Retained Earnings |
|
$27.63 B | $31.53 B | $35.26 B | $37.55 B | $47.26 B |
| Total Shareholder Equity |
|
$32.78 B | $35.80 B | $36.69 B | $38.60 B | $47.66 B |
| Common Stock |
|
$24.15 B | $24.47 B | $24.71 B | $24.87 B | $25.15 B |
Abbott Laboratories Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$3.33 B | $3.54 B | $3.27 B | $3.24 B | $3.22 B |
| Dividends Payout |
|
-$2.56 B | -$3.20 B | -$3.31 B | -$3.56 B | -$3.84 B |
| Capital Expenditures (Capex) |
|
-$2.18 B | -$1.89 B | -$1.78 B | -$2.20 B | -$2.21 B |
| Free Cash Flow (FCF) |
|
$5.72 B | $8.65 B | $7.80 B | $5.06 B | $6.35 B |
Abbott Laboratories Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$19.61 B | $24.54 B | $24.51 B | $22.13 B | $23.24 B |
| Gross Profit Margin (%) |
|
56.65% | 56.97% | 56.15% | 55.18% | 55.41% |
| Operating Income |
|
$5.36 B | $8.43 B | $8.36 B | $6.48 B | $6.83 B |
| Operating Income Margin (%) |
|
15.48% | 19.56% | 19.16% | 16.15% | 16.27% |
| Net Income |
|
$4.50 B | $7.07 B | $6.93 B | $5.72 B | $13.40 B |
| Net Income Margin (%) |
|
12.99% | 16.42% | 15.88% | 14.27% | 31.95% |
| EBITDA |
|
$8.79 B | $12.74 B | $12.38 B | $10.61 B | $10.83 B |
| EBITDA Margin (%) |
|
25.40% | 29.58% | 28.36% | 26.44% | 25.83% |
Abbott Laboratories Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
13.71% | 19.75% | 18.90% | 14.83% | 28.12% |
| Return on Assets (ROA) |
|
6.20% | 9.40% | 9.31% | 7.82% | 16.46% |
| Debt to Equity |
|
59.93% | 53.09% | 48.29% | 41.12% | 31.51% |
| Debt to total asset |
|
27.08% | 25.28% | 23.80% | 21.68% | 18.45% |
| Enterprise value to revenue |
|
5.98 | 6.01 | 4.59 | 4.98 | 4.85 |
| Enterprise value to EBITDA |
|
23.55 | 20.33 | 16.18 | 18.84 | 18.76 |
| Enterprise value |
|
$206.94 B | $259.02 B | $200.30 B | $199.85 B | $203.28 B |
| Cash to Debt |
|
40.21% | 55.42% | 54.08% | 45.74% | 56.97% |
| Tax Rate (%) |
|
10.00% | 13.88% | 16.53% | 14.12% | -91.10% |
| Payout Ratio |
|
56.95% | 45.28% | 47.73% | 62.14% | 28.62% |
